More Videos
SPECIAL REPORT
MOST SHARED
- The Executive Job Search
- Where Do Pardoned Turkeys Go?
- Salvation Army's Kettles Now Credit Card-Ready
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- S&P Stocks Trading at New 52-Week Highs
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Oil Friday
- Trader Talk
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Seeks Debt Delay, Stokes Default Fears
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Bankruptcies Jump, Hitting Highest Level in Four Years
- AIG, Ex-CEO Greenberg Reach Pact to Settle Disputes
- Bank of America CEO Search May Extend Into 2010
- Steepest Black Friday Discounts, Revealed
- Fed to Counsel Moviegoers on How to Use Credit Cards
- 'Cancer of Fraud' Permeates Health Care System: Critics
- Where Do Pardoned Turkeys Go?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
The only thing I wanted to mention was that while I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly [LLY
Loading...
()
] saying something along the lines of, "Coming Soon: Effient (Prasugrel)."
I went back to the site today and refreshed it over and over and over again, but that strip doesn't seem to be there anymore. Trust me. I saw it with my own eyes.
Effient is the blood-thinner that the Food and Drug Administration is expected to approve between now and September 26. So, unless the FDA pulls a fast one, I guess my call that the agency would have a problem with the connotation of a drug called Effient may have been wrong.
We'll see. No matter what it's named, I think it's interesting that a major drug company is advertising a drug to doctors before it's approved. Perhaps it's an indication that LLY is feeling pretty confident it's gonna get a thumbs-up soon.
Meantime, a company I'd never heard of until yesterday, Sciele Pharma [SCRX
Loading...
()
], is getting a lot of investor attention today. I even had to call Caris & Company analyst David Moskowitz (formerly of FBR) to find out how to pronounce it, because when I called two numbers at the Atlanta-based biopharma this morning, all I got was a fast busy signal. (Moskowitz says it's Sci-al.)
Sciele, a stock that has an average daily volume of less than one million shares, at midday has seen more than 21 million shares change hands, so far. They're up about 60 percent because one of Japan's biggest drug companies announced yesterday morning that it's gonna buy SCRX for $1.4 billion. I don't want this to sound xenophobic, but it's yet another example of a foreign firm scooping up an American company. And it's another example of a huge premium being paid for a baby biotech.
P.S. I was doing the aforementioned work on the Merck [MRK
Loading...
()
] /Schering-Plough [SGP
Loading...
()
] Vytorin studies on my laptop while training back from Charlottesville, VA where I watched the USC Trojans trounce the 'Hoos (another name I'd never heard of until this past weekend). Great town, great campus and stadium, by the way.
And the Starbucks right across from the U is one of the nicest I've ever seen -- and this grande, skim, no-whipped, two-Splenda mocha addict has seen quite a few. The only problem is that it was freezing cold on the second level where everyone hangs out and reads. The manager told me she's told corporate about it, but that she couldn't control the thermostat. Hello, Howard?
Bring on the Buckeyes!
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes